Speaker Profile
Ph.D., CEO, Boltz
Biography
Gabriele Corso is the CEO and co-founder of Boltz PBC, a company advancing biomolecular modeling and making it accessible to scientists. Gabriele received his PhD from MIT CSAIL, where he led the development of several of the most widely adopted AI models in drug discovery, now used by hundreds of thousands of scientists worldwide. Boltz develops state-of-the-art AI models for biomolecular design and has established major partnerships with leading pharmaceutical companies, including Pfizer, GSK, and Takeda, to accelerate the discovery and development of new therapeutics.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures & Gad Getz, Broad Institute
PMWC Award Ceremony
• David Baker, University of Washington (Nobel Laureate, Luminary)
Featured Speakers
• David Baker, University of Washington
• Jack Dent, Chai Discovery
• Dimitri Yatsenko, DataJoint
• Evgeny Kiner, Neosplice Therapeutics
• Alex Morgan, Khosla Ventures
• Gad Getz, Broad Institute
Causal Targets, Not Just Better Molecules
Using AI and human biology to improve target selection before chemistry begins.
Data Is the Moat
What proprietary, longitudinal, and perturbational data really confer advantage.
From Prediction to Patient
Patient stratification, smarter trials, and the handoff from model to clinic.
Designed Biology Meets Drug Development
AI-designed proteins, developability, and what survives contact with reality.
The Target Discovery Bottleneck
Why splicing and other underused biology may expand what is druggable.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
